Karine Le Malicot

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

snmjournals.org Favicon

redjournal.org Favicon

ejcancer.com Favicon

jnm.snmjournals.org

Articles

TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial

3 weeks ago | thelancet.com | Aziz Zaanan |Olivier Bouché |CHU Reims |Karine Le Malicot

aDepartment of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, University of Paris Cité, Paris, France bDepartment of Digestive Oncology, CHU Reims, Université Reims Champagne Ardenne, Reims, France cDepartment of Digestive Oncology, Centre Léon Bérard, Lyon, France dFédération Francophone de Cancérologie Digestive, EPICAD INSERM LNC-UMR 1231, Faculté de Médecine, University of Burgundy and Franche Comté, Dijon, France...

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →